Lexicon reports FDA's decision to extend review period for Zynquista

Lexicon Pharmaceuticals ( NASDAQ: LXRX) said that the FDA has asked for additional time to review additional data for the ...
Seeking Alpha

Lexicon Still Working Hard To Maximize The Value Of Sotagliflozin

Sotagliflozin won't die, and in the absence of a marketing partner, management is committed to pursuing FDA approval for the heart failure indication on their own. Upcoming studies of rival drugs ...
Ars Technica

JBL LSR305 - A great alternative to computer speakers if you have the space

OK, the Lexicon Alpha with good balanced cables is in place. There is no discernible background noise. Zero. YMMV if you have sensitive ears, but I can't hear anything, compared to it being so ...
Reuters

Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal

March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is licensing Lexicon Pharmaceuticals' (LXRX.O), opens new tab experimental obesity drug in a deal worth up to $1 billion, the Danish ...